Motley Fool contributor Brian Orelli shares why he loves this stock
Brian Orelli, biotech contributor and writer at The Motley Fool, joins the channel to discuss why he owns Novocure (NVCR 1.74%) stock. Check out his reasoning in this video!
*Stock prices used were the midday prices of Aug. 10, 2022. The video was published on Aug. 21, 2022.
Brian Orelli, PhD has positions in Novocure. Connor Allen has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Novocure. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
